The 57-year-old man was underwent sigmoid colostomy due to unresectable rectal carcinoma. Then he was treated with chemotherapy of levofolinate/5-fluorouracil/oxaliplatin(FOLFOX). After completion of 12 courses of chemotherapy, MR revealed responses. The patient underwent a low anterior resection. Preoperative chemotherapy with FOLFOX appears a promising regimen for patients with unresectable rectal cancer.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
INDEPSO-ISPSM consensus on peritoneal malignancies - Enhanced recovery after surgery in cytoreductive surgery (CRS) with/without hyperthermic intraperitoneal chemotherapy (HIPEC).
Gynecol Oncol Rep
February 2025
Dept of Surgical Oncology, Aster International Institute of Oncology, Bangalore, India.
Background: The role of enhanced recovery after surgery (ERAS) in cytoreductive surgery and/or Hyperthermic Intraperitoneal Chemotherapy HIPEC) is evolving, with promising results that improve patient outcomes. This consensus exercise was carried out to address and standardize components of the ERAS protocol pertinent to the Indian context.
Method: The modified Delphi method was employed with two rounds of voting.
Neoadjuvant chemoradiotherapy up-regulates PD-L1 in radioresistant colorectal cancer.
Clin Transl Radiat Oncol
March 2025
Institute of Medical Science & Institute for Cancer Research, Keimyung University, Daegu, Republic of Korea.
Background: Combining radiotherapy (RT) with immune checkpoint inhibitors (ICIs) is a promising strategy that can enhance the therapeutic efficacy of ICIs. However, little is known about RT-induced changes in the expression of immune checkpoints, such as PD-L1, and their clinical implications in colorectal cancer (CRC). This study aimed to investigate the association between responsiveness to RT and changes in PD-L1 expression in human CRC tissue and cell lines.
View Article and Find Full Text PDFA non-randomised open-label exploratory 'window of opportunity' study of TG02 treatment in patients with locally advanced primary and recurrent mutant colorectal cancer.
Heliyon
January 2025
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia.
Background: TG02 is a peptide-based cancer vaccine eliciting immune responses to oncogenic codon 12/13 mutations. This phase 1 clinical trial (NCT02933944) assessed the safety and immunological efficacy of TG02 adjuvanted by GM-CSF in patients with -mutant colorectal cancer.
Methods: In the interval between completing CRT and pelvic exenteration, patients with resectable mutation-positive, locally advanced primary or current colorectal cancer, received 5-6 doses of TG02/GM-CSF.
Relationship Between Radiation Therapy and Fecal Incontinence in Patients Treated for Localized Prostate Cancer: Results of the French ICONES Study.
Prostate
January 2025
AP-HP. Department of Urology, Henri Mondor University Hospital, Creteil, France.
Background: Radiation-induced late fecal incontinence (LFI) is one of the most quality-of-life impairing symptoms in prostate cancer. We aimed to assess the impact of radiotherapy (RT) technique and dose-volume effects on LFI using a robust score.
Methods: We identified 409 patients who underwent curative intent using standard fractionated radiation therapy, 190 of them were finally included and analyzed.
Fluorescence angiography with indocyanine green for low anterior resection in patients with rectal cancer: a prospective before and after study.
Tech Coloproctol
January 2025
Université Laval, 10, De l'Espinay St, Quebec City, QC, G1L 3L5, Canada.
Background: Inadequate bowel perfusion is among risk factors for colorectal anastomotic leaks. Perfusion can be assessed with indocyanine green fluorescence angiography (ICG) during colon resections. Possible benefits from its systematic use in high-risk patients with rectal cancer remain inconsistent.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!